Patient ID,Drug name,Analyte,Specimen,Population,Pregnancy stage,Pediatric/Gestational age,Parameter type,Parameter unit,Parameter value,Time value,Time unit
1,Infliximab,Infliximab,Maternal serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Maternal,µg/mL,25.3,23,days
2,Infliximab,Infliximab,Maternal serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Maternal,µg/mL,12.0,57,days
3,Infliximab,Infliximab,Maternal serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Maternal,µg/mL,17.0,31,days
4,Etanercept,Etanercept,Maternal serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Maternal,µg/mL,3.0,4,days
5,Etanercept,Etanercept,Maternal serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Maternal,µg/mL,<0.1,29,days
6,Etanercept,Etanercept,Maternal serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Maternal,µg/mL,0.2,16,days
1,Infliximab,Infliximab,Cord serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Cord,µg/mL,29.8,23,Day
2,Infliximab,Infliximab,Cord serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Cord,µg/mL,24.0,57,Day
3,Infliximab,Infliximab,Cord serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Cord,µg/mL,29.0,31,Day
4,Etanercept,Etanercept,Cord serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Cord,µg/mL,0.1,4,Day
5,Etanercept,Etanercept,Cord serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Cord,µg/mL,<0.1,29,Day
6,Etanercept,Etanercept,Cord serum,Maternal,N/A,N/A,TNF inhibitor-(µg/mL serum)-Cord,µg/mL,NA,16,Day
1,Infliximab,Infliximab,Placenta tissue,Maternal,N/A,N/A,TNF inhibitor-Mean ± SD (µg/g tissue)-Placenta,µg/g tissue,5.8 ± 0.9,23,days
2,Infliximab,Infliximab,Placenta tissue,Maternal,N/A,N/A,TNF inhibitor-Mean ± SD (µg/g tissue)-Placenta,µg/g tissue,1.8 ± 0.0,57,days
3,Infliximab,Infliximab,Placenta tissue,Maternal,N/A,N/A,TNF inhibitor-Mean ± SD (µg/g tissue)-Placenta,µg/g tissue,4.8 ± 1.5,31,days
4,Etanercept,Etanercept,Placenta tissue,Maternal,N/A,N/A,TNF inhibitor-Mean ± SD (µg/g tissue)-Placenta,µg/g tissue,0.1 ± 0.1,4,days
5,Etanercept,Etanercept,Placenta tissue,Maternal,N/A,N/A,TNF inhibitor-Mean ± SD (µg/g tissue)-Placenta,µg/g tissue,<0.1,29,days
6,Etanercept,Etanercept,Placenta tissue,Maternal,N/A,N/A,TNF inhibitor-Mean ± SD (µg/g tissue)-Placenta,µg/g tissue,<0.1,16,days
1,Infliximab,Infliximab,Cord serum,Maternal,N/A,N/A,Cord‐to‐maternal ratio-Cord‐to‐maternal ratio-Cord‐to‐maternal ratio,ratio,1.18,23,Day
2,Infliximab,Infliximab,Cord serum,Maternal,N/A,N/A,Cord‐to‐maternal ratio-Cord‐to‐maternal ratio-Cord‐to‐maternal ratio,ratio,2.00,57,Day
3,Infliximab,Infliximab,Cord serum,Maternal,N/A,N/A,Cord‐to‐maternal ratio-Cord‐to‐maternal ratio-Cord‐to‐maternal ratio,ratio,1.71,31,Day
4,Etanercept,Etanercept,Cord serum,Maternal,N/A,N/A,Cord‐to‐maternal ratio-Cord‐to‐maternal ratio-Cord‐to‐maternal ratio,ratio,0.04,4,Day
5,Etanercept,Etanercept,Cord serum,Maternal,N/A,N/A,Cord‐to‐maternal ratio-Cord‐to‐maternal ratio-Cord‐to‐maternal ratio,ratio,NA,29,Day
6,Etanercept,Etanercept,Cord serum,Maternal,N/A,N/A,Cord‐to‐maternal ratio-Cord‐to‐maternal ratio-Cord‐to‐maternal ratio,ratio,NA,16,Day
1,Infliximab,Infliximab,Placenta tissue,Maternal,N/A,N/A,Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio,ratio,0.35,23,days
2,Infliximab,Infliximab,Placenta tissue,Maternal,N/A,N/A,Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio,ratio,0.23,57,days
3,Infliximab,Infliximab,Placenta tissue,Maternal,N/A,N/A,Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio,ratio,0.44,31,days
4,Etanercept,Etanercept,Placenta tissue,Maternal,N/A,N/A,Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio,ratio,0.03,4,days
5,Etanercept,Etanercept,Placenta tissue,Maternal,N/A,N/A,Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio,ratio,NA,29,days
6,Etanercept,Etanercept,Placenta tissue,Maternal,N/A,N/A,Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio-Placenta‐to‐maternal ratio,ratio,NA,16,days
